Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19318720 | 0.96 | BACE1 (0.43) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| SCHEMBL25922433 | 0.95 | BACE1 (0.42) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL30759300 | 0.95 | BACE1 (0.42) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| SCHEMBL23824307 | 0.95 | BACE1 (0.42) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL31656498 | 0.93 | BACE1 (0.41) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| SCHEMBL22490451 | 0.93 | BACE1 (0.44) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| SCHEMBL12773357 | 0.93 | BACE1 (0.44) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL29510787 | 0.91 | BACE1 (0.43) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| SCHEMBL30749401 | 0.86 | BACE1 (0.41) | BACE1CTSCKMT2ACYP1A2ALOX15 | |
| SCHEMBL17811560 | 0.85 | BACE1 (0.40) | BACE1KMT2ACYP1A2ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023044171-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | BACE1 781/4885CTSC 3700/4885KMT2A 1963/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | BACE1 307/4885CTSC 22/4885KMT2A 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.